Circulating microparticle tissue factor, thromboembolism and survival in pancreaticobiliary cancers

Bharthuar, Anubha; Khorana, Alok A.; Hutson, Alan D.; Wang, Jingguo; Key, Nigel S.; Mackman, Nigel; Iyer, Renuka

doi:10.1016/j.thromres.2013.06.026

Cited by 114 publications

(103 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Increased levels of tissue factor expressing MPs were found to be indicative of the presence of an aggressive, metastatic and poorly differentiated malignant pancreatic state that could easily infiltrate peripancreatic vessels in patients [68]. Consistent with this was the strong association with thrombosis and increased mortality in patients with pancreaticobiliary cancers [69].…”

Section: Role Of Mps As Biomarkers Of Cancermentioning

confidence: 72%

Microparticles in cancer: A review of recent developments and the potential for clinical application

Gong

Jaiswal

Dalla

et al. 2015

Seminars in Cell & Developmental Biology

View full text Add to dashboard Cite

Once thought of as inert remnants of cellular processes, the significance of membrane vesicles is now expanding as their capacity to package and transfer bioactive molecules during intercellular communication is established. This ability to serve as vectors in the trafficking of cellular cargo is of mounting interest in the context of cancer, particularly in the dissemination of deleterious cancer traits from parent cells to recipient cells. Although microparticles (MPs) contribute to the pathogenesis of cancer, their unique characteristics can also be also exploited in the context of cancer treatment. The detection of MPs in body fluids has the potential to provide an effective means for the diagnosis, prognosis and surveillance of cancer patients. The use of such easily accessible systemic biomarkers that reflect the characteristics of the parent cells circumvents the need for invasive biopsy procedures. In addition, the autologous nature of MPs may allow them to be used as novel therapeutic drug carriers. Thus the modulation of MP vesiculation, the detection of MPs in disease monitoring, and the application of MPs as therapeutic delivery vehicles present prospective clinical interventions in the treatment of cancer. Revision Notes1. The authors overviewed the contribution of microparticles (MPs) to the pathogenesis of cancer and the potential for clinical application of MPs. In contrast to the title of the manuscript "Microparticles in Cancer: A Review of Recent Developments and the Potential for Clinical Application.", a large part of the content of this manuscript occupied the refer and discussed on the publications of the authors' group. The authors should discuss more generally on state-of-the-art for clinical application of MPs or some other extracellular vesicles (EVs). The authors have now included an extra section on Page 10 discussing the clinical applications of extracellular vesicles in cancer.2. The authors should refer to sufficient publications in general, especially in cancer-derived extracellular vesicles.Other references relevant to this study have now been added.3. The term "microparticles" mainly used in this manuscript is not well documented. Is there any specific differences between MPs and EVs? If so please describe those appropriately in the text. An explanation has now been added on Page 3 to describe the different membrane vesicles.4. The authors described "exosomes" in the text in the section 4. However, there is no mentioned the differ from MPs. This is a very confusing. An explanation of the different membrane vesicles has now been included on Page 3.5. The content of the figure is a very limited information. Modify the figure more generously including more other findings on tumor metastasis and drug resistance. Additional figures have now been included. Revision NotesAbbreviations: Matrix metalloproteinases, MMPs; mesenchymal stem cells, MSC; MPs, microparticles; miRNA, microRNA; microvesicles, MVs; MDR, multidrug resistance; non-small cell lung carcinoma, NSCLC; P-gp, P...

show abstract

Section: Role Of Mps As Biomarkers Of Cancermentioning

confidence: 72%

Microparticles in cancer: A review of recent developments and the potential for clinical application

Gong

Jaiswal

Dalla

et al. 2015

Seminars in Cell & Developmental Biology

View full text Add to dashboard Cite

show abstract

“…These patients are part of the Roswell Park Cancer Institute Data Bank and Biorepository. 97 Blood was collected from each patient after cancer diagnosis. In this study, elevated plasma MP TF activity was associated with the future development of VTE and decreased survival.…”

Section: Prospective Studiesmentioning

confidence: 99%

“…In this study, elevated plasma MP TF activity was associated with the future development of VTE and decreased survival. 97 Timing of sample collection for the prediction of future VTE in patients with cancer A general issue with prospective studies is that the collection of blood samples may occur many months before the thrombotic event. Most studies rely on a single sample to predict future events.…”

Section: Prospective Studiesmentioning

confidence: 99%

Tumor-derived tissue factor–positive microparticles and venous thrombosis in cancer patients

Geddings

Mackman

2013

Blood

Self Cite

289

238

View full text Add to dashboard Cite

Patients with cancer have an increased risk for venous thrombosis. Interestingly, different cancer types have different rates of thrombosis, with pancreatic cancer having one of the highest rates. However, the mechanisms responsible for the increase in venous thrombosis in patients with cancer are not understood. Tissue factor (TF) is a transmembrane receptor and primary initiator of blood coagulation. Tumor cells express TF and spontaneously release TF-positive microparticles (MPs) into the blood. MPs are small membrane vesicles that are highly procoagulant. It has been proposed that these circulating tumor-derived, TF-positive MPs may explain the increased rates of venous thrombosis seen in patients with cancer. In animal models, increased levels of tumor-derived, TF-positive MPs are associated with activation of coagulation. Moreover, these MPs bind to sites of vascular injury and enhance thrombosis. We and others have found that patients with cancer have elevated levels of circulating TF-positive MPs. These MPs are derived from tumors because they express tumor markers and are decreased by tumor resection. Importantly, several studies have shown that increased levels of TF-positive MPs correlate with venous thrombosis in patients with cancer. Taken together, these results suggest that TF-positive MPs may be a useful biomarker to identify patients with cancer who are at high risk for thrombosis.

show abstract

“…The levels of circulating tissue factor bearing MP (TF + MPs) [84] or phosphatidylserine (PS + ) and lactadherin + MPs [85] are higher in patients with a hypercoagulable status than in control subjects. Elevated circulating MP-TF activity is associated with thrombosis and worsened survival in patients with pancreaticobiliary cancers (PBCs) [86]. Increased levels of glial-derived and/or TF + MPs are also noted in glioblastoma multiforme (GBM) patients both before and even more so after the neoplasm is treated, suggesting a contribution of TF + /GFAP-MPs to the risk of VTE [87].…”

Section: Microparticles: a Potential Biomarker For Ptementioning

confidence: 99%

Recent Progress in Research on the Pathogenesis of Pulmonary Thromboembolism: An Old Story with New Perspectives

Yan

Wang

et al. 2017

BioMed Research International

View full text Add to dashboard Cite

Pulmonary thromboembolism (PTE) is part of a larger clinicopathological entity, venous thromboembolism. It is also a complex, multifactorial disorder divided into four major disease processes including venous thrombosis, thrombus in transit, acute pulmonary embolism, and pulmonary circulation reconstruction. Even when treated, some patients develop chronic thromboembolic pulmonary hypertension. PTE is also a common fatal type of pulmonary vascular disease worldwide, but earlier studies primarily focused on the pathological changes in the blood component of the disease. With contemporary advances in molecular and cellular biology, people are becoming increasingly aware of coagulation pathways, the function of vascular smooth muscle cells, microparticles, and the inflammatory pathways that play key roles in PTE. Combined hypoxia and immune research has revealed that PTE should be regarded as a class of complex diseases caused by multiple factors involving the vascular microenvironment and vascular cell dysfunction.

show abstract

Circulating microparticle tissue factor, thromboembolism and survival in pancreaticobiliary cancers

Cited by 114 publications

References 31 publications

Microparticles in cancer: A review of recent developments and the potential for clinical application

Microparticles in cancer: A review of recent developments and the potential for clinical application

Tumor-derived tissue factor–positive microparticles and venous thrombosis in cancer patients

Recent Progress in Research on the Pathogenesis of Pulmonary Thromboembolism: An Old Story with New Perspectives

Contact Info

Product

Resources

About